PEK
0.325
170.8%
JAY
0.001
-50%
CHM
0.008
60%
LNR
0.001
-50%
AJL
0.008
33.3%
ECS
0.009
-25%
ATX
0.07
27.3%
ERL
0.003
-25%
EDU
0.165
26.9%
OSL
0.003
-25%
HCF
0.033
26.9%
RMY
0.026
-21.2%
SHP
0.005
25%
DTM
0.004
-20%
8CO
0.017
21.4%
HTA
0.02
-20%
EPM
0.006
20%
RDN
0.004
-20%
IPT
0.006
20%
ORD
0.41
-18%
MEM
0.006
20%
EVR
0.005
-16.7%
FRM
0.285
18.8%
KPO
0.005
-16.7%
H2G
0.013
18.2%
NWM
0.01
-16.7%
LMG
0.013
18.2%
ROG
0.005
-16.7%
PCL
0.013
18.2%
AZ9
0.027
-15.6%
RMI
0.013
18.2%
FFF
0.006
-14.3%
E79
0.027
17.4%
HHR
0.006
-14.3%
HE8
0.014
16.7%
KLI
0.03
-14.3%
1AE
0.074
15.6%
KNB
0.078
-14.3%
NIM
0.115
15%
PGY
0.006
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Recce Pharmaceuticals (ASX:RCE) reveals successful batch completion under Good Manufacturing Practices

Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), a company developing a New Class of Synthetic Anti-Infectives, announces successful batch completion under Good Manufacturing Practices (GMP) for RECCE® 327 with the patented manufacturing process now producing 5,000 GMP doses of R327 per week.

Highlights

  • Successful production of 5,000 x RECCE® 327 (R327) doses per week under GMP campaign.
  • R327 manufactured under GMP standards in support of present Phase I, Phase II and anticipated Registrational Phase III clinical trials, demonstrating compliance with guidelines set by regulatory authorities, such as the U.S. Food and Drug Administration.

 

Commentary 

Recce Pharmaceuticals’ Head of Manufacturing Arthur Kollaras said “We are thrilled to
announce the successful batch completion of human pharmaceutical grade R327, representing
a crucial step forward in our mission to address the global threat of antimicrobial resistance.”